TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02908776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
Study: NCT05181969

Intervention type: DEVICE
Intervention: Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)
Description: Lipoprotein apheresis Method I

Intervention type: DEVICE
Intervention: Lipid filtration (Octo Nova®, Diamed Medizintechnik)
Description: Lipoprotein apheresis Method II

Intervention type: DEVICE
Intervention: Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)
Description: Lipoprotein apheresis Method III

Intervention type: DEVICE
Intervention: Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)
Description: Lipoprotein apheresis Method IV
Study: NCT01665690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient delivered partner therapy
Description: The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted public health partner services
Description: During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
Study: NCT02989363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Not device O-Arm in DBS
Description: Deep brain stimulation surgeries without the device O-Arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Not device O-Arm in RAQUIS
Description: Complex back surgeries without the device O-Arm
Study: NCT04574154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIB
Description: FIB with ultrasound: Ropivacaine 0.5% 40 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: bupivacaine 0,5% 2.2 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: bupivacaine 0,5% 2.2 ml
Study: NCT02617563

Intervention type: DEVICE
Intervention: Minimally invasive lumbar fusion
Description: Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
Study: NCT01187290

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: neoadjuvant chemoradiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
Study: NCT01491958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Day +1, +3, and +6 and +11
Study: NCT03279978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01367743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine perfusion
Description: perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine perfusion
Description: perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
Study: NCT04553887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: single agent, 110mg p.o once daily until disease progressed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: single agent, 110mg p.o once daily until disease progressed
Study: NCT01979510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0663B
Description: MK-0663B once daily for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOLOCAM PLUS®
Description: DOLOCAM PLUS® once daily for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg
Description: Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg
Description: Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
Study: NCT03401606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
Study: NCT01581411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator
Description: Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
Study: NCT02045199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : V0111 cream
Description: Application twice a day during 28 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application twice a day during 28 days
Study: NCT04237883

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard communication email
Description: This is the base communication that all physicians will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard communication email
Description: This is the base communication that all physicians will receive.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study: NCT04237883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard communication email
Description: This is the base communication that all physicians will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social comparison Intervention
Description: The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social comparison Intervention
Description: The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Training
Description: Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
Study: NCT02655198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
Study: NCT01980446

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auditory-evoked potentials
Description: cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
Study: NCT02012816

Intervention type: OTHER
Group type: OTHER
Intervention: Peer-referral incentive program to increase VMMC uptake
Description: The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally
Study: NCT00656214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: 08 mg/day in two divided dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two divided dosage
Study: NCT04416516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo cranial irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo cranial irradiation
Study: NCT04416516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
Study: NCT00016302

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo cranial irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study: NCT02813538

Intervention type: DRUG
Intervention: Indocyanine green clearance
Description: To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance

Intervention type: OTHER
Intervention: Thromboelastometry
Description: To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
Study: NCT02589587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: lean control group
Study: NCT04707248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6000a
Description: Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6000a
Description: Intravenous administration at RDE on Day 1 of Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6000a
Description: Intravenous administration at RDE on Day 1 of Cycle 1
Study: NCT05978869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical fitness training
Description: Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
Study: NCT01344122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KPI training only
Description: See comparison arm description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KPI plus OLI
Description: See experimental arm description.
Study: NCT03719573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention
Description: A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
Study: NCT02243176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: The dose of saxaglitpin will be 5mg oral qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
Study: NCT02997930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: A measure of general cognition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Clock Drawing Test Command and Copy
Description: A measure of current cognition using digital pen technology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wide Range Achievement Test reading subtest
Description: A measure of premorbid intellectual estimate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test (HVLT)
Description: A measure of declarative memory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Depression Scale (GDS)
Description: A measure of the of presence of depression.
Study: NCT04033679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TDCS
Description: Participants will receive active TDCS stimulation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Participants will receive sham TDCS stimulation.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study: NCT02981212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: combination with Mycophenolate Mofetil
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study: NCT02981212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB
Description: maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
Study: NCT00419250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study: NCT00419250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study: NCT00608465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 5 mg x 1 week followed by 10 mg x 9 weeks.
Study: NCT00016302

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo craniocervical radiotherapy
Study: NCT00608465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
Study: NCT01609933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: ABT-450 (tablets) dosed with ritonavir (capsules or tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 (tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a (pegIFN)
Description: pegIFN alpha-2a (syringe)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (tablets)
Study: NCT00016302

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo craniocervical radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo craniocervical radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies